Serum levels of macrophage colony-stimulating factor in trophoblastic disease

Ernest I. Kohorn, Barry M. Kacinski, E. Richard Stanley

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives. The aims of this study were to measure levels of colony stimulating factor (CSF-1) in patients with trophoblastic disease, to determine whether such measurement may be useful to supplement measurement of the prognostically reliable human chorionic gonadotrophin (hCG), and to assess whether measurement of CSF-1 may be helpful in predicting requirement for chemotherapy in patients with hydatidiform mole. Methods. Serial weekly serum samples were selected for CSF-1 assay from representative diagnostic groups of patients with trophoblastic disease: hydatidiform-mole with spontaneous resolution, low-risk post-hydatidiform-mole trophoblastic tumor, partial hydatidiform mole, high-risk metastatic gestational trophoblastic tumor, primary ovarian choriocarcinoma, and placental site trophoblastic tumor, hCG was measured by an in-house radioimmunoassay that measures all parts of the hCG molecule. CSF-1 was measured by radioimmunoassay with 125I-labeled recombinant CSF-1. The upper level of normal CSF-1 was taken as 8 ng/ml. Results. In this study of 45 patients with trophoblastic disease, some very high levels of CSF-1 were encountered. In a few patients there was dramatic correlation with hCG. Generally, however, CSF-1 and hCG did not correlate. CSF-1 was frequently not elevated when hCG was still significantly elevated and conversely CSF-1 was elevated when hCG was negative. Conclusion: The measurement of CSF-1 does not appear to be useful in managing trophoblastic disease as it does not correlate with the level of hCG. Occasionally, high levels of CSF-1 were found in patients with trophoblastic disease.

Original languageEnglish (US)
Pages (from-to)383-386
Number of pages4
JournalGynecologic Oncology
Volume80
Issue number3
DOIs
StatePublished - 2001

Fingerprint

Macrophage Colony-Stimulating Factor
Chorionic Gonadotropin
Serum
Hydatidiform Mole
Trophoblastic Neoplasms
Radioimmunoassay
Placental Site Trophoblastic Tumor
Choriocarcinoma

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Serum levels of macrophage colony-stimulating factor in trophoblastic disease. / Kohorn, Ernest I.; Kacinski, Barry M.; Stanley, E. Richard.

In: Gynecologic Oncology, Vol. 80, No. 3, 2001, p. 383-386.

Research output: Contribution to journalArticle

Kohorn, Ernest I. ; Kacinski, Barry M. ; Stanley, E. Richard. / Serum levels of macrophage colony-stimulating factor in trophoblastic disease. In: Gynecologic Oncology. 2001 ; Vol. 80, No. 3. pp. 383-386.
@article{419834ba8db441d3b11bb9946d8034c5,
title = "Serum levels of macrophage colony-stimulating factor in trophoblastic disease",
abstract = "Objectives. The aims of this study were to measure levels of colony stimulating factor (CSF-1) in patients with trophoblastic disease, to determine whether such measurement may be useful to supplement measurement of the prognostically reliable human chorionic gonadotrophin (hCG), and to assess whether measurement of CSF-1 may be helpful in predicting requirement for chemotherapy in patients with hydatidiform mole. Methods. Serial weekly serum samples were selected for CSF-1 assay from representative diagnostic groups of patients with trophoblastic disease: hydatidiform-mole with spontaneous resolution, low-risk post-hydatidiform-mole trophoblastic tumor, partial hydatidiform mole, high-risk metastatic gestational trophoblastic tumor, primary ovarian choriocarcinoma, and placental site trophoblastic tumor, hCG was measured by an in-house radioimmunoassay that measures all parts of the hCG molecule. CSF-1 was measured by radioimmunoassay with 125I-labeled recombinant CSF-1. The upper level of normal CSF-1 was taken as 8 ng/ml. Results. In this study of 45 patients with trophoblastic disease, some very high levels of CSF-1 were encountered. In a few patients there was dramatic correlation with hCG. Generally, however, CSF-1 and hCG did not correlate. CSF-1 was frequently not elevated when hCG was still significantly elevated and conversely CSF-1 was elevated when hCG was negative. Conclusion: The measurement of CSF-1 does not appear to be useful in managing trophoblastic disease as it does not correlate with the level of hCG. Occasionally, high levels of CSF-1 were found in patients with trophoblastic disease.",
author = "Kohorn, {Ernest I.} and Kacinski, {Barry M.} and Stanley, {E. Richard}",
year = "2001",
doi = "10.1006/gyno.2000.6090",
language = "English (US)",
volume = "80",
pages = "383--386",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Serum levels of macrophage colony-stimulating factor in trophoblastic disease

AU - Kohorn, Ernest I.

AU - Kacinski, Barry M.

AU - Stanley, E. Richard

PY - 2001

Y1 - 2001

N2 - Objectives. The aims of this study were to measure levels of colony stimulating factor (CSF-1) in patients with trophoblastic disease, to determine whether such measurement may be useful to supplement measurement of the prognostically reliable human chorionic gonadotrophin (hCG), and to assess whether measurement of CSF-1 may be helpful in predicting requirement for chemotherapy in patients with hydatidiform mole. Methods. Serial weekly serum samples were selected for CSF-1 assay from representative diagnostic groups of patients with trophoblastic disease: hydatidiform-mole with spontaneous resolution, low-risk post-hydatidiform-mole trophoblastic tumor, partial hydatidiform mole, high-risk metastatic gestational trophoblastic tumor, primary ovarian choriocarcinoma, and placental site trophoblastic tumor, hCG was measured by an in-house radioimmunoassay that measures all parts of the hCG molecule. CSF-1 was measured by radioimmunoassay with 125I-labeled recombinant CSF-1. The upper level of normal CSF-1 was taken as 8 ng/ml. Results. In this study of 45 patients with trophoblastic disease, some very high levels of CSF-1 were encountered. In a few patients there was dramatic correlation with hCG. Generally, however, CSF-1 and hCG did not correlate. CSF-1 was frequently not elevated when hCG was still significantly elevated and conversely CSF-1 was elevated when hCG was negative. Conclusion: The measurement of CSF-1 does not appear to be useful in managing trophoblastic disease as it does not correlate with the level of hCG. Occasionally, high levels of CSF-1 were found in patients with trophoblastic disease.

AB - Objectives. The aims of this study were to measure levels of colony stimulating factor (CSF-1) in patients with trophoblastic disease, to determine whether such measurement may be useful to supplement measurement of the prognostically reliable human chorionic gonadotrophin (hCG), and to assess whether measurement of CSF-1 may be helpful in predicting requirement for chemotherapy in patients with hydatidiform mole. Methods. Serial weekly serum samples were selected for CSF-1 assay from representative diagnostic groups of patients with trophoblastic disease: hydatidiform-mole with spontaneous resolution, low-risk post-hydatidiform-mole trophoblastic tumor, partial hydatidiform mole, high-risk metastatic gestational trophoblastic tumor, primary ovarian choriocarcinoma, and placental site trophoblastic tumor, hCG was measured by an in-house radioimmunoassay that measures all parts of the hCG molecule. CSF-1 was measured by radioimmunoassay with 125I-labeled recombinant CSF-1. The upper level of normal CSF-1 was taken as 8 ng/ml. Results. In this study of 45 patients with trophoblastic disease, some very high levels of CSF-1 were encountered. In a few patients there was dramatic correlation with hCG. Generally, however, CSF-1 and hCG did not correlate. CSF-1 was frequently not elevated when hCG was still significantly elevated and conversely CSF-1 was elevated when hCG was negative. Conclusion: The measurement of CSF-1 does not appear to be useful in managing trophoblastic disease as it does not correlate with the level of hCG. Occasionally, high levels of CSF-1 were found in patients with trophoblastic disease.

UR - http://www.scopus.com/inward/record.url?scp=0035093331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035093331&partnerID=8YFLogxK

U2 - 10.1006/gyno.2000.6090

DO - 10.1006/gyno.2000.6090

M3 - Article

C2 - 11263936

AN - SCOPUS:0035093331

VL - 80

SP - 383

EP - 386

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -